FOX
39
2
WU
38
18
MHK
40
6
VRSK
40
-2
CSCO
57
3
NFLX
62
3
MPC
54
2
NWL
23
4
AKAM
45
2
SBUX
50
-2
PEP
59
-4
DE
35
-3
ABT
50
2
CAT
72
3
EXR
35
2
KR
65
-6
MSFT
60
3
AIZ
73
2
PRGO
53
3
FRT
53
2
FOX
39
2
WU
38
18
MHK
40
6
VRSK
40
-2
CSCO
57
3
NFLX
62
3
MPC
54
2
NWL
23
4
AKAM
45
2
SBUX
50
-2
PEP
59
-4
DE
35
-3
ABT
50
2
CAT
72
3
EXR
35
2
KR
65
-6
MSFT
60
3
AIZ
73
2
PRGO
53
3
FRT
53
2
Financhill
Back

Intellia Therapeutics Quote, Financials, Valuation and Earnings

My #1 Coin is...

All the details are on the next page.
Sell
24

NTLA
Intellia Therapeutics

Last Price:
21.26
Seasonality Move:
34.01%

7 Day Trial

ALL ACCESS PASS

$ 7

Master the Market: The Formula for a 96.3% Win Rate Revealed!

Act now!

Intellia Therapeutics Price Quote

$21.26
-0.27 (-1.25%)
(Updated: April 24, 2024 at 1:50 PM ET)

Intellia Therapeutics Key Stats

Sell
24
Intellia Therapeutics (NTLA) is a Sell
Day range:
$21.50 - $22.85
52-week range:
$20.78 - $47.48
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
53.06
P/B ratio:
1.97%
Volume:
699.4K
Avg. volume:
1.2M
1-year change:
-42.03%
Market cap:
$2.1B
Revenue:
$36.3M
EPS:
$-5.41

How Much Does Intellia Therapeutics Make?

Is Intellia Therapeutics Growing As A Company?

Data Unavailable

Intellia Therapeutics Stock Price Performance

What Is Intellia Therapeutics 52-Week High & Low?

Intellia Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Intellia Therapeutics?

Is Intellia Therapeutics Cash Flow Positive?

  • What Is NTLA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$394.1M
  • What Is Intellia Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $130.3M
  • What Is Intellia Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$31.3M

Intellia Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    NTLA return on invested capital is -42.82%
  • What Is Intellia Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -35.35%
  • What Is NTLA Return On Equity?
    ROE is a measure of profitability and is -42.82%

Intellia Therapeutics Earnings Date & Stock Price

Intellia Therapeutics Competitors

Intellia Therapeutics Dividend Yield

Data Unavailable

Intellia Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.72%
Revenue: 0% -116.88%

Analyst Recommendations

Buy Recommendations: 17
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 71.12
Upside from Last Price: 230.33%

Major Shareholders

  • How many NTLA shares are owned by institutional investors?
    122M NTLA shares are owned by institutional investors
  • How many NTLA shares are owned by insiders?
    2.8M NTLA shares are owned by insiders